These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25251078)

  • 1. Life cycle analysis within pharmaceutical process optimization and intensification: case study of active pharmaceutical ingredient production.
    Ott D; Kralisch D; Denčić I; Hessel V; Laribi Y; Perrichon PD; Berguerand C; Kiwi-Minsker L; Loeb P
    ChemSusChem; 2014 Dec; 7(12):3521-33. PubMed ID: 25251078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active pharmaceutical ingredient (API) production involving continuous processes--a process system engineering (PSE)-assisted design framework.
    Cervera-Padrell AE; Skovby T; Kiil S; Gani R; Gernaey KV
    Eur J Pharm Biopharm; 2012 Oct; 82(2):437-56. PubMed ID: 22820647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raw material variability of an active pharmaceutical ingredient and its relevance for processability in secondary continuous pharmaceutical manufacturing.
    Stauffer F; Vanhoorne V; Pilcer G; Chavez PF; Rome S; Schubert MA; Aerts L; De Beer T
    Eur J Pharm Biopharm; 2018 Jun; 127():92-103. PubMed ID: 29452241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design.
    Ticehurst MD; Marziano I
    J Pharm Pharmacol; 2015 Jun; 67(6):782-802. PubMed ID: 25677227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solid form screening--a review.
    Aaltonen J; Allesø M; Mirza S; Koradia V; Gordon KC; Rantanen J
    Eur J Pharm Biopharm; 2009 Jan; 71(1):23-37. PubMed ID: 18715549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous processing and the applications of online tools in pharmaceutical product manufacture: developments and examples.
    Ooi SM; Sarkar S; van Varenbergh G; Schoeters K; Heng PW
    Ther Deliv; 2013 Apr; 4(4):463-70. PubMed ID: 23557287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting and controlling API crystal form for pharmaceutical development--strategies and processes.
    Yin SX; Grosso JA
    Curr Opin Drug Discov Devel; 2008 Nov; 11(6):771-7. PubMed ID: 18946842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of cocrystals in pharmaceutical science.
    Shan N; Zaworotko MJ
    Drug Discov Today; 2008 May; 13(9-10):440-6. PubMed ID: 18468562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous processes for the production of pharmaceutical intermediates and active pharmaceutical ingredients.
    LaPorte TL; Wang C
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):738-45. PubMed ID: 17987525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
    Verbeeck RK; Kanfer I; Walker RB
    Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding pharmaceutical polymorphic transformations I: influence of process variables and storage conditions.
    Sood J; Sapra B; Bhandari S; Jindal M; Tiwary AK
    Ther Deliv; 2014 Oct; 5(10):1123-42. PubMed ID: 25418270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of Raman spectroscopy to the analysis of phase transformations in pharmaceutical compounds.
    Hédoux A; Guinet Y; Descamps M
    Int J Pharm; 2011 Sep; 417(1-2):17-31. PubMed ID: 21256937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments in hydrogenation technology for fine-chemical and pharmaceutical applications.
    Machado RM; Heier KR; Broekhuis RR
    Curr Opin Drug Discov Devel; 2001 Nov; 4(6):745-55. PubMed ID: 11899614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic engineering: the ultimate paradigm for continuous pharmaceutical manufacturing.
    Yadav VG; Stephanopoulos G
    ChemSusChem; 2014 Jul; 7(7):1847-53. PubMed ID: 24719301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic reactor design approach for the synthesis of active pharmaceutical ingredients.
    Emenike VN; Schenkendorf R; Krewer U
    Eur J Pharm Biopharm; 2018 May; 126():75-88. PubMed ID: 28536050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simple assessment of homogeneity in pharmaceutical mixing processes using a near-infrared reflectance probe and control charts.
    Skibsted ET; Boelens HF; Westerhuis JA; Witte DT; Smilde AK
    J Pharm Biomed Anal; 2006 Apr; 41(1):26-35. PubMed ID: 16289623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early chemical development at Legacy Wyeth Research.
    O'Brien MK; Kolb M; Connolly TJ; McWilliams JC; Sutherland K
    Drug Discov Today; 2011 Jan; 16(1-2):81-8. PubMed ID: 21111844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation of tablets containing an 'in-process' amorphized active pharmaceutical ingredient.
    Jójárt-Laczkovich O; Szabó-Révész P
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1272-81. PubMed ID: 21457129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.